Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Protagonist Therapeutics Inc banner

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 83.88 USD 0.67%
Market Cap: $5.2B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

PTGX Price Targets Summary
Protagonist Therapeutics Inc

Wall Street analysts forecast PTGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PTGX is 102.55 USD with a low forecast of 65.65 USD and a high forecast of 123.9 USD.

PTGX Lowest Forecast
Wall Street Target
65.65 USD
-22% Downside
PTGX Average Forecast
Wall Street Target
102.55 USD
22% Upside
PTGX Highest Forecast
Wall Street Target
123.9 USD
48% Upside
Lowest
Price Target
65.65 USD
22% Downside
Average
Price Target
102.55 USD
22% Upside
Highest
Price Target
123.9 USD
48% Upside
Protagonist Therapeutics Inc Competitors:
Price Targets
WLFC
Willis Lease Finance Corp
-20% Downside
NN
NextNav Inc
26% Upside
CSGP
CoStar Group Inc
69% Upside
HOTH
Hoth Therapeutics Inc
437% Upside
WLFC
Willis Lease Finance Corp
-20% Downside
NN
NextNav Inc
26% Upside
CSGP
CoStar Group Inc
69% Upside
HOTH
Hoth Therapeutics Inc
437% Upside
CFFN
Capitol Federal Financial Inc
5% Upside
ELAN
Elanco Animal Health Inc
5% Upside
QLYS
Qualys Inc
32% Upside

Revenue
Forecast

N/A
Past Growth
-11% / Year
Estimated Growth
Estimates Accuracy
11%
Average Beat
N/A
Past Growth
-11% / Year
Estimated Growth
Estimates Accuracy
11%
Average Beat

The compound annual growth rate of Protagonist Therapeutics Inc's revenue for the next 4 years is -11%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
-39% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
-39% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate of Protagonist Therapeutics Inc's operating income for the next 4 years is -39%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
-27% / Year
Estimated Growth
Estimates Accuracy
-47%
Average Miss
N/A
Past Growth
-27% / Year
Estimated Growth
Estimates Accuracy
-47%
Average Miss

The compound annual growth rate of Protagonist Therapeutics Inc's net income for the next 4 years is -27%.

What are analyst estimates?

See Also

Summary
PTGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
PTGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PTGX stock valuation using valuation multiples.
Wall Street Estimates
PTGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PTGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PTGX's stock price target?
Price Target
102.55 USD

According to Wall Street analysts, the average 1-year price target for PTGX is 102.55 USD with a low forecast of 65.65 USD and a high forecast of 123.9 USD.

What is Protagonist Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%

The compound annual growth rate of Protagonist Therapeutics Inc's revenue for the next 4 years is -11%.

What is Protagonist Therapeutics Inc's Operating Income forecast?
Projected CAGR
-39%

The compound annual growth rate of Protagonist Therapeutics Inc's operating income for the next 4 years is -39%.

What is Protagonist Therapeutics Inc's Net Income forecast?
Projected CAGR
-27%

The compound annual growth rate of Protagonist Therapeutics Inc's net income for the next 4 years is -27%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.